HRT Should Generally Not Be Started After Age 60
Starting hormone replacement therapy (HRT) after age 60 is not recommended due to significantly increased risks of cancer, stroke, and cardiovascular events that outweigh potential benefits.
The Evidence Against Late Initiation
The most recent high-quality research from 2026 demonstrates that initiating HRT at age 65 or older is associated with more than doubled cancer risk (HR: 2.22) and nearly tripled stroke risk (HR: 2.70) 1. This represents substantial harm that cannot be justified for symptom management alone.
The 2022 NAMS guideline explicitly states that for women initiating HRT more than 10 years from menopause onset or aged older than 60 years, the benefit-risk ratio is unfavorable due to greater absolute risks of coronary heart disease, stroke, venous thromboembolism, and dementia 2. This is the current standard of care.
The Critical "Window of Opportunity"
HRT safety depends heavily on timing:
- Before age 60 OR within 10 years of menopause: Favorable benefit-risk ratio 2
- After age 60 OR more than 10 years from menopause: Unfavorable benefit-risk ratio 2
This "timing hypothesis" is consistently supported across guidelines. The USPSTF recommends against HRT for chronic disease prevention in postmenopausal women 3, and both the American Heart Association and ACOG specifically recommend against its use for cardiovascular prevention 3.
Specific Risks in Women Over 60
When HRT is started late, the hazards are substantial:
- Cerebrovascular events: 2.7-fold increased risk 1
- Any cancer: 2.2-fold increased risk 1
- Breast cancer: Increased risk with estrogen-progestogen combinations 1
- Cardiovascular disease: No protective benefit when started late; potential harm 3, 2
- Dementia: Increased risk in older initiators 2
The One Exception: Local Vaginal Therapy
For isolated genitourinary symptoms in women over 60, low-dose vaginal estrogen is appropriate and safe 2. This is distinct from systemic HRT because:
- Minimal systemic absorption
- Targets specific local symptoms
- Does not carry the same cardiovascular and cancer risks as systemic therapy
- Can be used without age restrictions for genitourinary syndrome of menopause 2
Common Pitfalls to Avoid
Don't confuse continuation with initiation: Women who started HRT before age 60 and continue it may have a different risk profile than new initiators 4, though even continuation requires careful reassessment
Don't assume "bioidentical" hormones are safer: The FDA has not approved bioidentical hormones for chronic disease prevention, and no randomized trials support their safety in this population 3
Don't use HRT for disease prevention in older women: The evidence clearly shows harm, not benefit, for cardiovascular protection, dementia prevention, or osteoporosis prevention when initiated after age 60 3, 2
What to Do Instead
For symptomatic women over 60:
- For vasomotor symptoms: Consider non-hormonal options (SSRIs, SNRIs, gabapentin, cognitive behavioral therapy)
- For genitourinary symptoms: Use low-dose vaginal estrogen, vaginal DHEA, or ospemifene 2
- For osteoporosis: Use bisphosphonates, denosumab, or other bone-specific therapies—not systemic HRT
The evidence is clear: systemic HRT should not be initiated after age 60 due to unfavorable risk-benefit ratio, with the sole exception of low-dose vaginal estrogen for local genitourinary symptoms.